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sets of mice expressing different SOD1 mutants, which
in each case provoke disease with elevated (Wong et
al., 1995) or unchanged (Ripps et al., 1995; Bruijn et
al., 1997b) SOD1 activity, while SOD1 null mice live to
adulthood and do not develop motor neuron disease
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(Reaume et al., 1996). Further, some mutants such as
SOD1G37R retain full specific activity (Borchelt et al.,
The sixth anniversary has just passed since the land- 1994), while neither the age of onset nor rapidity of
mark discovery (Rosen et al., 1993) that mutation in the progression of human disease correlate with dismutase
enzyme superoxide dismutase 1 (SOD1) is a primary activity levels (Cudkowicz et al., 1997). The inescapable
cause of a proportion of a dominantly inherited form conclusion from this abundance of evidence is that the
of amyotrophic lateral sclerosis (ALS), more familiarly mutants have acquired one or more toxic properties,
known in the United States as Lou Gehrig's disease. irrespective of the amount of SOD1 activity each retains.
First described by Charcot 124 years before that, the
primary characteristic of this disease is the selective The Copper-Mediated, Oxidative Damage Hypothesis
degeneration and death of upper and lower motor neu- Of the proposals to explain how more than 65 different
rons, initiating in mid adult life and almost invariably mutations scattered throughout the SOD1 polypeptide
progressing to paralysis and death over a 1±5 year time can mediate the same neurodegenerative disease, the
course. While dominant inheritance accounts for only most prominent one ascribes toxicity to less tightly
about 10% of the instances of disease, and SOD1 muta- folded enzymes that perform aberrant copper-mediated
tions comprise fewer than 20% of those (reviewed by chemistry due to greater access of abnormal substrates
Brown, 1995), the genetics provided an enormous injec- to the active site copper. A slight modification is that
tion of hope for dissecting the mechanism of disease, the mutants may handle the copper clumsily, frequently
its neuronal selectivity, and the timing of disease onset releasing it, with the free copper catalyzing unwanted
and for identifying therapeutic approaches. oxidative chemistry. Consistent with aberrant copper-
Four primary hypotheses for contributors to disease mediated catalysis, a common property of the mutants,
mechanism have now emerged: (1) oxidative damage, including those in histidines that directly coordinate the
an idea obviously provoked by the discovery of SOD1 copper, is that they do bind the copper in at least one
mutations; (2) axonal strangulation from neurofilamen- in vivo setting (Corson et al., 1998).
tous disorganization, supported by misaccumulated A first aberrant substrate proposed (Beckman et al.,
neurofilaments as a hallmark of pathology in many cases 1993) was peroxynitrite (2ONOO), which can form spon-
of sporadic and SOD1-mediated familial disease; (3) tox- taneously from superoxide and nitric oxide and, when
icity arising from intracellular aggregates and/or failure used as a substrate, yields tyrosine nitration (Figure
of protein folding or degradation, a common feature of 1B). Despite divergent evidence from several groups
SOD1 mutant±mediated disease; and (4) excitotoxicity (primarily using immunocytochemistry) for whether ele-
from aberrant handling of glutamate, particularly arising vated levels of the predicted nitrotyrosine are present
from missplicing of a glutamate transporter mRNA. in either SOD1-mediated disease in mouse and humans,
Where do these issues now lie? evidence from manipulating SOD1 activity levels in mice
makes the peroxynitrite hypothesis unlikely to play a
SOD1 Mutants Confer a Toxic Property(ies) central role. In mice that develop disease from express-
That mutation in SOD1 could be a primary cause of ing a mutant (SOD1G85R) that confers only a z10% in-
selective motor neuron degeneration was initially any- crease in SOD1 activity over the endogenous, wild-type
thing but obvious. Ubiquitously expressed, the known SOD1, neither elimination nor elevation (by z6-fold) of
activity of this 153-amino-acid, cytoplasmic homodimer wild-type SOD1 affected disease onset, progression, or
is to convert superoxide, produced primarily by errors pathology (Bruijn et al., 1998). The insensitivity of toxicity
of oxidative phosphorylation in mitochondria, to water to SOD1 activity levels is inconsistent with damage aris-
and hydrogen peroxide. Catalysis is mediated in two ing from superoxide or any spontaneous reaction prod-
asymmetric steps by an essential copper atom, which uct of it (such as 2ONOO), since absence of the wild-type
is alternately reduced and then oxidized by superoxide protein would accelerate toxicity by raising superoxide
(Figure 1A). While early measurements of SOD1 activity levels and/or forcing all catalysis through the mutant,
in patient blood suggested loss of enzymatic activity while elevating it would do the opposite. This was clearly
to be central to the mechanism of disease, an initial not the case, at least for the SOD1G85R mutant.
transgenic mouse expressing familial ALS±linked mu- A second proposed aberrant substrate is hydrogen
tant SOD1G93A (i.e., glycine substituted to alanine at posi- peroxide, the normal end product released from the
tion 93) developed progressive motor neuron disease oxidized form of the enzyme (Cu21±SOD1). Use of perox-
despite markedly elevated SOD1 activity levels (Gurney ide by the reduced Cu1±SOD1 form, on the other hand,
et al., 1994). This has been extended by three additional may produce the extraordinarily reactive hydroxyl radi-
cal (Figure 1C), thereby leading to a cascade of peroxi-
dation. A 2- to 4-fold increased utilization in vitro of*E-mail: dcleveland@ucsd.edu.
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Whatever the case, the seminal discovery that copper
acquisition by SOD1 in yeast requires CCS, a specific
copper chaperone for SOD1 (Culotta et al., 1997), has
allowed design of a test in a single experiment of all
possible, copper-mediated toxicities. Since both the
human wild-type and mutant SOD1s apparently load
copper in vivo through the action of a mammalian
CCS (Corson et al., 1998), production of SOD1 mutant±
expressing mice that are also deleted for the single
mammalian CCS will directly test the requirement for
copper (and any catalyzed oxidative damage) in SOD1
mutant toxicity. This experiment, which has the power
to disprove copper-mediated oxidative mechanisms
should toxicity prove insensitive to copper loading, is
well underway in at least one group (P. Wong, personal
communication), with a clear answer anticipated by
early next year.
Neurofilaments as Contributors and Risk Factors
in ALS
From early reports of pathology of both sporadic (Hirano
et al., 1984a) and familial (Hirano et al., 1984b) ALS,
neurofilament misaccumulations in the cell bodies and
proximal axons of motor neurons have been established
to be hallmarks of the disease. With the further demon-
stration that transgenes encoding mutant neurofilament
subunits could directly cause selective degeneration
and death of motor neurons and the ensuing axonal
disorganization, this led to the proposal that damage to
Figure 1. SOD1 Chemistries neurofilaments was directly involved in ALS patho-
(A) Normal SOD1 chemistry: SOD1-mediated dismutation of super- genesis.
oxide in two asymmetric steps.
A pair of genetic experiments has now demonstrated(B and C) Proposed toxic chemistries from use of aberrant sub-
that this is true even in the case of disease initiallystrates.
provoked by mutant SOD1. By using gene disruption(B) Protein nitration from 2ONOO.
(C) Hydroxyl radical formation from hydrogen peroxide. to eliminate neurofilaments from mice expressing the
SOD1G85R mutant, onset and progression of disease has
been found to be slowed by 40 days, despite the sig-
nificant initial disadvantage of loss of z15% of motorhydrogen peroxide as a substrate by two mutants (rela-
neurons early in postnatal life arising from absence oftive to wild-type SOD1) has been reported (Wiedau-
neurofilaments (Williamson et al., 1998). Even more pro-Pazos et al., 1996), although this has been directly chal-
vocative is that decreasing the axonal amount of neuro-lenged on technical grounds (Singh et al., 1998). Also,
filaments, by trapping most in the cell bodies throughwhether a higher level of peroxidation will arise from
transgene-increased expression of the large neurofila-such a mechanism is also not settled, since the fewfold
ment subunit NF-H, extends life span in SOD1G37R miceincrease by the mutant SOD1 (compared to wild type)
by 6 months (a 65% increase in longevity) (Couillard-in peroxide usage could easily be more than counterbal-
Despres et al., 1998). While several other strategies haveanced by the decreased stability (and hence accumu-
successfully slowed disease in SOD1 mice (see below),lated level) of many mutants.
this last neurofilament strategy represents by far the
most striking slowing of disease. Indeed, since neurofil-Testing the Oxidative Hypothesis
aments are determinants of axonal diameter and onlyIn testing the proposals for aberrant substrates, in-
the largest caliber, neurofilament-rich motor axons arecreased levels of markers of oxidative damage (protein
lost in human disease (Kawamura et al., 1981) or SOD1carbonyls, products of hydroxyl radical damage, protein
mutant±mediated disease in mice (Bruijn et al., 1997),nitration) have been reported in disease in some (Fer-
the simple view is that neurofilament content representsrante et al., 1997; Andrus et al., 1998) of the transgenic
one of the factors underlying selective vulnerability.mice but not others (Bruijn et al., 1997a), and in some but
not all examples of sporadic or SOD1-mediated familial
ALS (E.g., Bowling et al., 1993). Amid such divergent Genetic Evidence for Neurofilament Mutations
as Cause or Risk Factor in ALSfindings, no conclusion can yet be drawn as to whether,
or to what degree, oxidative damage plays a role in The evidence that in mice mutant neurofilaments could
directly provoke motor neuron disease and the accom-disease. And there may, of course, be yet unidentified
alternative substrates of mutant SOD1 that initiate a panying neurofilamentous misaccumulation fueled ef-
forts to test whether neurofilament mutations underliecascade of oxidatively damaged products that have
been overlooked by the conventional assays. disease. Early efforts focused on the 80% of familial
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Figure 2. Mutations in Sporadic and Familial ALS Found in the Gene Encoding the Large Neurofilament Subunit NF-H
ALS not arising from SOD1 mutation but did not identify delivery of selected transport cargoes. Since neurofila-
ments are a major cargo whose presence slows theneurofilament mutants. Subsequent efforts examining
the repetitive tail domain of the large neurofilament sub- speed of slow transport, this offers at least a partial
explanation for the vulnerability of the large motor axonsunit NF-H, especially the extensive study of Al-Chalabi
et al. (1998), have now identified a set of small in-frame at risk. The motor neurons, with large, neurofilament-
rich axons that in humans are up to a meter in length,deletions or insertions in z1% of more than 1300 ALS
patients, almost all of which appear in ªsporadicº cases are among the body's longest and largest cells (up to
5000 times the volume of a typical cell), almost all com-(Figure 2). Excluding family members not yet affected,
no similar mutants have been seen in a comparable ponents of which must be transported into and along
the axon.number of control DNAs. Search of this one domain
alone has thus yielded mutations in the overall patient
population about half as frequent as SOD1 mutants. It Intracellular Aggregates of SOD1: Are They Toxic?
should be realized that variation in timing of disease Studies of several neurodegenerative diseases (Alzhei-
onset and incomplete penetrance can befuddle identi- mer's disease, prion diseases, triplet repeat expansion
fying an underlying genetic component. While the known diseases such as Huntington's) have revealed a com-
neurofilament sequence variants are surely not by them- mon feature: protein aggregates. This commonality has
selves capable of provoking disease with high pene- fueled a long-standing debate over whether these ag-
trance, the collective evidence now strongly hints that gregates are key to the pathogenesis, harmless byprod-
variants in neurofilaments are, at the least, important ucts, or potentially beneficial through sequestration of
risk factors for apparently sporadic disease. aberrant products. The likelihood that aggregates might
be contributors to ALS was significantly boosted by
the finding that all examples of SOD1 mutant±mediatedAxonal Strangulation from Chronic Deficits
in Transport disease in mice develop prominent, cytoplasmic, intra-
cellular inclusions in motor neurons, and in some casesBecause biosynthesis of macromolecules is almost
completely restricted to neuronal cell bodies, axonal within the astrocytes surrounding them as well. These
aggregates develop by the onset of clinical disease, intransport is especially crucial to the long, large caliber
motor axons. The known neurofilament-dependent slow- some cases (e.g., SOD1G85R mice) representing the first
pathologic sign of disease, and later increase markedlying of axonal transport, combined with the prominent
misaccumulation of neurofilaments in ALS, suggested in abundance during disease progression (Bruijn et al.,
1997).that an important aspect of toxicity may arise from dam-
age to transport. Chronic deficits in transport of selec- As to their composition, the striking feature is that
aggregates are intensely immunoreactive with antibod-tive cargoes of slow transport have now been seen as
very early features, initiating up to 5 months prior to ies to SOD1, a feature common not only to all instances
of disease in mice but also to several SOD1-mediatedclinical disease onset in mice expressing SOD1G85R and
SOD1G37R mutants (Williamson and Cleveland, 1999). human examples (see Bruijn et al., 1998, and references
therein). Reported as well in a handful of sporadic casesDeficits in fast transport have been seen prior to disease
onset in SOD1G93A mice (Warita et al., 1999). Thus, (but not in others), such aggregates may prove to be a
frequent feature even of sporadic disease, but a conclu-whether arising from direct damage to the machinery
or cargoes of transport or secondary to other primary sive outcome awaits a more systematic test.
The aggregates are of two kinds. The first class con-damage, a common deficit from SOD1 mutants that pro-
voke different pathologies is chronically compromised tains those identifiable by conventional histological stains,
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Figure 3. Proposed Mechanisms of, and Pos-
sible Therapies for, Motor Neuron Toxicity in
ALS
Events within motor neurons are marked in
black; events within astroctyes are in green.
Potential therapeutic steps are marked in
blue.
which most frequently reveal intense, concentrated spinal motor neurons, glutamate recovery is the job of
astrocytes, which synthesize the major spinal cordSOD1 immunoreactivity throughout the inclusion or, less
frequently, only at the periphery of it. The second class transporter EAAT2 (previously known as GLT-1). For
ALS, early evidence for involvement of glutamate cameincludes more diffusely staining perikaryal deposits.
Mating SOD1 mutant mice to mice deleted at the endog- from the demonstration of selective, local loss of EAAT2:
affected tissue regions from about two-thirds of spo-enous SOD1 alleles or to mice expressing wild-type
SOD1 to six times the normal level has shown that the radic ALS patients were found to have up to 95% losses
in EAAT2 levels and activity (Rothstein et al., 1995).timing, abundance, and staining intensities of the aggre-
gates are independent of wild-type SOD1. While immu- Mechanistically, this does not arise from mutation but
apparently from selective errors in splicing of the EAAT2nocytochemistry is among the world's worst quantita-
tive tools, it seems safe to conclude that mutant SOD1 mRNA. This has been reported within affected, but not
unaffected, regions of the two-thirds of sporadic pa-is one primary component of these aggregates.
Aggregation, or at least misfolded subunits, is thus tients that show diminished glutamate transport activity
(Lin et al., 1998). In fact, evidence for many aberrantlyapparently a characteristic of the SOD1 mutants. This
has been reproduced selectively in motor neurons by spliced RNA species was reported, with two prominent
products either with exon 9 skipped or intron 7 retained.microinjection of genes encoding mutant but not wild
type SOD1. This approach has yielded what may be the Both make nonfunctional truncated products, and the
latter dominantly inhibits normal EAAT2-mediated trans-best in vitro model of disease, including aggregates
selectively in motor (but not sensory or hippocampal) port.
These powerful findings strongly support a role forneurons (Durham et al., 1997), followed by cell death
that can be slowed by apoptosis inhibitors. Aspects astrocytic dysfunction as an important component of
motor neuron death. Moreover, using DNA microinjec-of toxicity may arise either through aberrant chemistry
mediated by the misfolded aggregated mutants or tion into Xenopus oocytes, ALS-linked SOD1 mutants,
but not wild-type SOD1, were found to catalyze inactiva-through loss by coprecipitation of an essential compo-
nent or components, for example, by saturating the pro- tion of EAAT2 in the presence of high levels of hydrogen
peroxide (Trotti et al., 1999). When combined with promi-tein degradation machinery and/or protein folding chap-
erones. Consistent with the latter, increasing the level of nent SOD1-immunoreactive aggregates in astrocytes in
sporadic and SOD1-mediated disease in humans andthe stress-inducible chaperone HSP 70 reduced mutant-
driven aggregates and ameliorated toxicity in this in vitro mice, this promotes the satisfying hypothesis that dam-
age within astrocytes initiated either by SOD1 mutationcell model (Bruening et al., 1999). It should be noted that
the outcome of the test of influence of copper loading per se or by other (yet unidentified) initiators yields di-
minished defense from synaptic glutamate as a key as-on toxicity (see above) will probably bear directly on
distinguishing the potential contributions of copper ca- pect of the cascade of toxicity. Not only would this, at
last, offer a direct mechanistic link between sporadictalysis versus aggregation.
and SOD1-mediated disease, but it raises the possibility
that the underlying toxicity could be partly or exclusivelyExcitotoxicity and Glutamate Transporters: Are
Astrocytes, Not Neurons, to Blame? of astrocytic origin. This should now be clearly testable
with transgenes expressed specifically in astrocytes orGlutamate-mediated excitotoxicity due to repetitive fir-
ing and/or elevation of intracellular calcium by calcium- motor neurons.
But a crucial fly in the ointment is that the strikinglypermeable glutamate receptors has been frequently
implicated in neuronal death. High-affinity glutamate abundant EAAT2 mRNA missplicing has not yet been
confirmed as a frequent feature of disease. Rather, onetransport is the primary means of rapid recovery of syn-
aptic glutamate, thereby suppressing this toxicity. For report (Nagai et al., 1998) finds similar levels of exon 8
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skipping and intron 7 retention in normal as well as axonal transport or direct damage to astrocytes, per-
haps provoking errors of mRNA maturation and gluta-patient samples; so too have other reports (not yet in
print) at recent neurology meetings. With the potential mate metabolism. Neurofilament mutations can be di-
rect causes of motor neuron disease in mice, and theirto directly link disease mechanism in the few SOD1-
mediated examples with the majority of sporadic dis- misorganization by mutation (or other covalent damage)
may also force chronic deficits in axonal transport thatease, confirming or refuting the effects on EAAT2 RNA
metabolism should now be an immediate goal. provoke initiation of a further cascade of cell death
events. Potential interventions (denoted in blue in Figure
3) can be imagined at several levels. If copper chemistryTreating Disease in Mice: Bcl-2 Expression, Caspase
is involved, attractive therapies could be inhibitors ofInhibition, or Creatine Slow Disease
the CCS required for loading copper onto SOD1. Alterna-The Bcl-2 family of genes has been widely implicated
tives would include a search for agents that affect neu-in regulating cell death. Using transgenes to force chron-
rofilament synthesis or assembly or anti-apoptoticically elevated postnatal expression of the cell death
agents to slow the cascade of events. And, we shouldinhibitor Bcl-2, Przdeborski and colleagues demon-
not forget the simple, practical relief that creatine hasstrated a significant (30±35 day) slowing of disease onset
provided in the SOD1G93A mouse. Replication of theseand extension of life span in SOD1G93A mice, without
findings in other mutants and an expeditious human trialeffect on length of disease progression (Kostic et al.,
should be first priorities.1997). Mechanistically, it is not yet clear whether the
positive effects of Bcl-2 are from acting as an antioxidant
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